Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin ; volume:65 ; number:S 01 ; year:2015 ; pages:S13-S13 ; 01
Drug research ; 65, Heft S 01 (2015), S13-S13, 01
- Beteiligte Personen und Organisationen
-
Marhardt, K.
Muurahainen, N.
- DOI
-
10.1055/s-0035-1558063
- URN
-
urn:nbn:de:101:1-2018112107031814893397
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Marhardt, K.
- Muurahainen, N.
Ähnliche Objekte (12)
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Current Disease-Modifying Therapies in Multiple Sclerosis
Disease-modifying effects of phosphocitrate and phosphocitrate-β-ethyl ester on partial meniscectomy-induced osteoarthritis
Disease-modifying treatments in Alzheimer’s disease
Efficacy of intra-articular injections of platelet-rich plasma as a symptom- and disease-modifying treatment for knee osteoarthritis - the RESTORE trial protocol
Bisphosphonates as disease-modifying drugs in osteoarthritis preclinical studies: a systematic review from 2000 to 2020
MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy
The disease-modifying effect of dehydroepiandrosterone in different stages of experimentally induced osteoarthritis: a histomorphometric study
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Disease-modifying effects of ranibizumab for central retinal vein occlusion
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Current Disease-Modifying Therapies in Multiple Sclerosis
Disease-modifying effects of phosphocitrate and phosphocitrate-β-ethyl ester on partial meniscectomy-induced osteoarthritis
Disease-modifying treatments in Alzheimer’s disease
Efficacy of intra-articular injections of platelet-rich plasma as a symptom- and disease-modifying treatment for knee osteoarthritis - the RESTORE trial protocol
Bisphosphonates as disease-modifying drugs in osteoarthritis preclinical studies: a systematic review from 2000 to 2020
MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy
The disease-modifying effect of dehydroepiandrosterone in different stages of experimentally induced osteoarthritis: a histomorphometric study
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Disease-modifying effects of ranibizumab for central retinal vein occlusion
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Current Disease-Modifying Therapies in Multiple Sclerosis
Disease-modifying effects of phosphocitrate and phosphocitrate-β-ethyl ester on partial meniscectomy-induced osteoarthritis
Disease-modifying treatments in Alzheimer’s disease
Efficacy of intra-articular injections of platelet-rich plasma as a symptom- and disease-modifying treatment for knee osteoarthritis - the RESTORE trial protocol
Bisphosphonates as disease-modifying drugs in osteoarthritis preclinical studies: a systematic review from 2000 to 2020
MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy
The disease-modifying effect of dehydroepiandrosterone in different stages of experimentally induced osteoarthritis: a histomorphometric study
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases